Compare ASST & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | AKBA |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.4M | 729.1M |
| IPO Year | 2023 | 2014 |
| Metric | ASST | AKBA |
|---|---|---|
| Price | $1.04 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 75.2M | 2.8M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,512,106.00 | ★ $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | N/A | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 125.01 | 32.49 |
| 52 Week Low | $0.73 | $1.45 |
| 52 Week High | $7.89 | $4.08 |
| Indicator | ASST | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 33.61 |
| Support Level | $0.73 | $1.58 |
| Resistance Level | $0.87 | $1.71 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 84.76 | 7.41 |
Strive Inc is engaged in providing investment advisory, wealth management, and consulting services through its subsidiary. Its objectives is to (i) accumulate Bitcoin; (ii) increase Bitcoin-per-share; and (iii) outperform Bitcoin over the long run by deploying both beta Bitcoin treasury accumulation strategies and alpha investment strategies with the goal of beating Bitcoin's investment performance as the hurdle rate.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.